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Abstract
Objective: To gather data about the medical and non-medical health service in patients suffering from post-stroke
spasticity of the upper limb and evaluate treatment effectiveness and tolerability as well as costs over the treatment
period of one year.
Methods: Prospective, non-interventional, multicenter, parallel-group study comparing effectivenessand costs of
incobotulinumtoxinA (INCO) treatment (n = 118) to conventional (CON) antispastic therapy (n = 110) for upper limb
spasticity after stroke in 47 clinical practices across Germany over a 1-year treatment period. IncobotulinumtoxinA
was applied according to the individual treatment algorithms of each participating site and additional antispastic
treatments were allowed. Primary efficacy objective was the reduction of the muscle tone measured by Ashworth
scale. Responder analyses and logistic regressions were performed. Quality of life, measured by SF-12 questionnaire
and functional disability were assessed. Besides calculating treatment costs, a cost-utility analysis was performed.
Results: Responder rates of all muscle groups of the upper extremities were significantly higher in the treatment
group (62.9–86.2 % vs. 15.5–26.9 %, p < 0.01). Total health service costs were twice as high in the INCO group,
however cost-utility ratios were consistently superior compared to the control group. Lowest incremental costs
were documented to improve the “physical health” dimension in quality of life.
Conclusion: Higher responder rates, higher increases in quality of life and superior cost-utility ratios in the
BoNT/A-treatment group underline guideline recommendations for botulinum toxin A treatment in focal or
segmental spasticity. Results may partially be influenced by different patient demographics or disease severity
at study entry.
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Background
Spasticity is a disorder of the sensorimotor system char-
acterized by a velocity-dependent increase in muscle
tone that interferes with limb positioning, grasping,
walking, self-care and other activities of daily living [1, 2].
It is a common complication for stroke survivors and is
often more severe in upper than lower limb muscles [2].
Prevalence estimates range from 4 % to 42.6 % with inci-
dences of disabling spasticity from 2 % to 13 % [3]. In
Germany, the incidence of stroke is about 150–200 in
100.000. 24 % of patients already show an increased
muscle tone in the affected extremities during the first
week after stroke [4]. Onset is highly variable and can
occur early within the first few weeks or more than a year
after stroke. 19–38 % of patients develop spasticity during
the first year after stroke. During the course of the disease,
contractures may evolve which lead to permanent painful
and deformed posture. Starting treatment early might be
effective in reducing contracture development and thus
functional impairments [5]. In German as well inter-
national guidelines and evidence based reviews [6–10],
BoNT/A is recommended as a treatment of choice for
focal, multifocal and regional spasticity and received level
A recommendation for the treatment of post-stroke spas-
ticity [11]. However, botulinum toxin treatment has so far
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not been implemented in routine health care practice in
Germany [12].
This prospective, multicenter, non-interventional parallel-
group study was performed to gather routine clinical prac-
tice data on post-stroke spasticity patients and their
treatments in Germany. Drug treatment as well as non-
pharmacological therapies were documented to analyze
efficacy, impact on quality of life and costs over a one year
treatment period. Conventional therapy was compared to
incobotulinumtoxinA (Xeomin®; Merz Pharmaceuticals
GmbH, Frankfurt/M, Germany), a BoNT/A preparation
free of complexing proteins [13]. Apart from the symp-
tomatic treatment of spasmodic torticollis and blepharo-
spasm, incobotulinumtoxinA is approved in Germany for
the treatment of post-stroke spasticity of the upper limb
presenting with flexed wrist and clenched fist in adults
[14]. IncobotulinumtoxinA is available in many countries
worldwide and is approved in US for upper limb spasticity
treatment.
Methods
The prospective, non-interventional, parallel-group study
was approved by the ethics committee of Hannover
Medical School (Germany) and conducted by the Institute
of Empirical Health Economics (Burscheid, Germany)
between April 2012 and May 2014 in accordance with the
Medicines Act of the Federal Republic of Germany. All
participating patients gave written informed consent.
The study compared two patient groups: One arm in-
cluded patients receiving conventional measures such as
oral antispastic medications, physiotherapy and others,
patients in the other arm received incobotulinumtoxinA
injections plus conventional therapy if required.
Patients in the INCO group were additionally sepa-
rated in patients who had received any botulinum toxin
treatment before study start (‘BoNT/A-pretreated’) and
those who were BoNT/A naïve, since pretreatment may
have an effect on the efficacy of the study treatment.
Due to the non-interventional study design treatment
decisions are solely at the discretion of the participating
physicians and the decision how to treat a particular pa-
tient (in this study with conventional therapy [CON] or
with incobotulinumtoxinA [INCO]) must be made be-
fore inclusion of the patient in the study. At study start
participating sites had chosen their respective treatment
group for all their patients.
Only adult patients were eligible for participation if they
suffered from post-stroke upper limb spasticity, were able
to read, to understand and complete information material
as well as a patient questionnaire. Patients were excluded
from the incobotulinumtoxinA arm in case of contraindi-
cations to BoNT/A preparations, such as infection at the
intended injection site or presence of neuromuscular dis-
orders (e.g. myasthenia gravis, Lambert-Eaton syndrome).
In case of a prior BoNT/A treatment, the last injection
should date back at least 12 weeks before study start.
The observation period covered one year. Treatment
in either group was started at Visit 1 (baseline visit) and
continued at visits every 12 weeks (visit 2, 3, 4) until the
end of observation (visit 5, visit 5b). Since peak effect of
botulinum toxin therapy occurs about four to six weeks
after the injection additional efficacy assessments in the
INCO group took place four weeks after the first, third
and fifth visit (visit 1b, visit 3b and visit 5b). For the con-
trol group, it was expected that systemic oral antispastic
medication will result in a steady treatment effect.
All antispastic medications including incobotulinum-
toxinA were prescribed according to the respective sum-
mary of product characteristics and physicians discretion.
Assessments
The primary goal of antispastic therapy is the reduction
of increased muscle tone. The 5-point Ashworth scale
presents an established and approved tool in the neuro-
logical practice [15, 16]. It measures the increase of
muscle tone by testing muscle resistance against passive
movements performed by the evaluating physician. A re-
duction by 1 point is considered clinically significant
[17, 18].
The primary efficacy parameter was a responder ana-
lysis at study end. Responders were defined as patients
with a 1-point or higher improvement (reduction) from
baseline in the Ashworth score from baseline to the
end of the study (visit 5 for the CON group, around
12 months of treatment; visit 5b for the INCO group,
around 13 months of treatment). Treatment groups
were compared using Fisher’s Exact Test. Only patients
with baseline values in Ashworth scale ≥ 1were considered
in the analysis. Responder analyses were performed for
each of the nine spasticity patterns of upper limb spasti-
city. Other assessment parameters were overall efficacy
and tolerability, both rated by physicians and patients on a
5-point scale. Functional disability was rated by the
physician and patient on the Disability Assessment
Scale (DAS) consisting of the four domains hygiene,
dressing, limb position and pain on a 4-point scale ranging
from ‘0 = no disability’ to ‘3 = severe disability’. P-values
for changes in functional disability over the course of
the study were calculated with the Wilcoxon-Mann–
Whitney test.
Therapy costs were considered from a societal perspec-
tive: Direct costs, indirect costs as well as intangible effects
in terms of health related quality of life were assessed quar-
terly. Costs related to the treatment of post-stroke spas-
ticity were calculated for the 1-year treatment period.
Direct costs included: Ambulatory medical treatment
(study centre visits, office based physicians visits), diag-
nostic procedures, drugs, non-pharmacological therapies,
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hospitalizations and other medical interventions (e.g. re-
habilitation measures), medical devices/therapeutic aids
and nursing home care. Cost data sources are listed in
Table 1. Therapy costs are paid by the statutory or private
health insurances of the patient. Indirect costs included
loss of productivity caused by post-stroke spasticity for pa-
tients capable of gainful employment. This includes days
absent from work and continuation of remuneration and
were valued monetarily based on the average income in
Germany.
Intangible effects refer to mental and physical burdens
patients suffer from and can hence not be measured
monetarily. They include pain, depression, social pres-
sure or limited mobility and are expressed by a rating of
quality of life. To evaluate intangible effects quality of
life was assessed with the “SF-12 v2 Health Survey”, a
shortened version of the SF-36 [19]. The SF-12 includes
12 items, which are subsumed in two dimensions ‘men-
tal health’ and ‘physical health’. SF-12 scores in this
study are calculated using a fixed algorithm and are
based on the analysis manual of the German norm from
1994. Possible scores in both domains range from 0 to
100, high scores indicating a high quality of life. Compari-
sons between baseline and end observation employed the
paired t-test.
Utility values in this study were responder rates in
Ashworth scale in the respective spasticity pattern and
changes in SF-12 scores in mental and physical health
after 1-year of antispastic treatment. Cost-utility ratios
were calculated by dividing yearly total costs per patient
by responder rates as well as the change in SF-12 scores
(utility values). The Incremental Cost-utility ratios
(ICER) was subsequently assessed according to the
formula: ICER = (Total costs INCO – Total costs CON)/
(Utility value INCO – Utility value CON). The ICER
permits the comparison of relative cost-effectiveness
between the treatment groups.
Results
A total of 218 patients were analysed. 108 patients re-
ceived incobotulinumtoxinA treatment, 110 patients were
treated with conventional therapeutic measures. 62 % in
the INCO group had received Botulinum neurotoxin prior
to study entry.
The majority of patients were male (58.7 %). The aver-
age age at baseline was 64.8 years (SD = 13.1). Patients
in the INCO group were about 6 years younger than in
the control group. First diagnosis of stroke and post-
stroke spasticity had occurred about 2 years earlier in
the INCO group (see Table 2). The majority of patients
(82.6 %) suffered from concomitant diseases, most com-
monly from high blood pressure (71.1 %), epilepsy (27.2 %)
and depression (26.1 %).
At the time of study start only 6.0 % of the patients
were still employed, most patients were retired (90.6 %).
20.4 % (CON group) and 60.6 % (INCO group) of the
patients had retired earlier due to spasticity. More pa-
tients in the INCO group (79.6) were in need of care
than in the CON group (64.4 %).
About every second patient (56.9 %) suffered from
spasticity of both the upper and lower limb. 54.2 % in
the INCO group and 32.1 % in the CON group suffer
from upper limb spasticity only (total: 43.1 %). The most
frequent clinical patterns of spasticity of the upper limb
were flexed elbow (85.8 % of all patients), flexed wrist
(71.6 %), shoulder adduction/internal rotation (71.1 %)
and clenched fist and forearm pronation (both 70.6 %).
Antispasticity treatment
In the incobotulinumtoxinA group, 38 % of the patients
were BoNT/A naïve. The remainder had received their last
BoNT/A injection a median 15.7 weeks (range 12–171
weeks) before start of study. Mean incobotulinumtoxinA
doses at first injection were 215 ± 114 U, at last (5th) injec-
tion 268.7 ± 155 U. Prior to start of study 38 patients in this
group (35.2 %) had received oral antispasticity medication
(mainly baclofen [63.2 %] and tolperisone [21.1 %]). Thirty-
seven (33.6 %) of the patients in the conventional therapy
arm had received oral antispasticity medication prior to
start of study (mainly baclofen [62.2 %], tetrazepam
[16.2 %], and tolperisone [10.8 %]). During the study
physicians documented oral antispastic medication in
19.1–32.4 % of patients in the INCO-group and 60.9–
69.2 % in the CON-group depending on the treatment
quarter (see Table 3). Most commonly prescribed in the
INCO group was baclofen (48.4–70 % of patients with
oral medication), in the CON group baclofen (45.6–
49.3 %) and tetrazepam (10.5–17.9 %). The proportion
of patients receiving any physiotherapy was slightly higher
in the CON group (54.5–61.9 % vs. 52.9–55.6 %); the
proportion of patients receiving occupational therapy was
markedly higher in the incobotulinumtoxinA group
Table 1 Cost data sources
Item Cost sources
Drugs German Rote Liste 2013, web-based research
Ambulatory
medical treatment
German value measurement (EBM 2000+)
and fee regulations for doctors (GOÄ)
Non-pharmacological
therapies
According to agreements between
German health insurance funds and
professional organizations




(G-DRG), web- and phone-based research




Average payments according to
German retirement insurance
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(39.8–46.8 % vs. 9.5–13.6 %). The use of additional
therapeutic aids such as ortheses etc. was markedly re-
duced in the last 3 months of incobotulinumtoxinA
treatment.
Responder analyses
Results of the primary efficacy parameter, responder ana-
lyses in Ashworth score from visit 1 to the end of the
study demonstrate clinically highly meaningful changes in
the INCO group compared to baseline for all clinical
patterns (see Table 4). BoNT/A-naïve benefit more than
pretreated patients. The results were highly significant for
all group comparisons between incobotulinumtoxinA
treatment and conventional antispastic treatment (Fisher´s
exact test, p < 0.01). The highest responder rate with con-
ventional therapy was 26.9 % (flexed elbow), whereas in
the INCO group, the lowest responder rate was 56.4 %
(shoulder adduction/internal rotation). Logistic regres-
sions (data not shown) indicate, that no significant influ-
ence of factors such as sex, age, BMI, time since diagnosis











Gender (m) 36 (53.7 %) 22 (53.7 %) 58 (53.7 %) 70 (63.6 %) 128 (58.7 %)
Age (years) 62.3 (10.7) 60.7 (16.0) 61.7 (12.9) 67.8 (12.7) 64.8 (13.1)
Body mass index (kg/m2) 26.7 (4.0) 26.8 (4.4) 26.7 (4.1) 27.7 (4.8) 27.2 (4.5)
Time since apoplex (years) 8.0 (5.6) 6.8 (6.1) 7.5 (5.8) 5.3 (5.1) 6.5 (5.6)
Time since spasticity (years) 6.9 (6.3) 6.0 (6.5) 6.6 (6.3) 4.9 (5.4) 5.7 (5.9)
Concomitant diseases (yes) 55 (82.1 %) 29 (70.7 %) 84 (77.8 %) 96 (87.3 %) 180 (8.6 %)
Employed (yes) 1 (1.5 %) 3 (7.3 %) 4 (3.7 %) 9 (8.2 %) 13 (6.0 %)
Retired (yes) 58 (96.7 %) 39 (97.5 %) 87 (94.6 %) 86 (86.9 %) 173 (90.6 %)
Early retirement due to spasticity (yes) 40 (63.5 %) 20 (55.6 %) 60 (60.6 %) 19 (20.4 %) 79 (41.1 %)
Reduction in earning capacity due to spasticity (yes) 22 (32.9 %) 11 (26.8 %) 33 (30.6 %) 23 (20.9 %) 56 (25.7 %)
Level of care (none) 12 (17.9 %) 10 (24.4 %) 22 (20.4 %) 37 (35.6 %) 59 (27.8 %)
Level 1 28 (41.8 %) 15 (36.6 %) 43 (39.8 %) 33 (31.7 %) 76 (35.8 %)
Level 2 23 (34.3 %) 15 (36.6 %) 38 (35.2 %) 29 (27.9 %) 67 (31.6 %)
Level 3 4 (6.0 %) 1 (2.4 %) 5 (4.6 %) 5 (4.8 %) 10 (4.7 %)
All values are means (± standard deviation) or number of patients (%)
Table 3 Overview of antispastic therapies and measures during the study
IncobotulinumtoxinA group: Antispastic medications except BoNT/A, non-pharmacological therapies and aids
First quarter (n = 108) Second quarter (n = 102) Third quarter (n = 99) Fourth quarter (n = 94)
Oral medication 31 (28.7 %) 23 (32.4 %) 20 (20.2 %) 18 (19.1 %)
Physical therapy 60 (55.6 %) 54 (52.9 %) 54 (54.5 %) 51 (54.3 %)
Occupational therapy 43 (39.8 %) 42 (41.2 %) 41 (41.4 %) 44 (46.8 %)
Speech therapy 10 (9.3 %) 8 (7.8 %) 8 (8.1 %) 9 (8.6 %)
Other therapies 3 (2.8 %) 6 (6.0 %) 4 (4.0 %) 4 (4.3 %)
Therapeutic aids 12 (11.0 %) 5 (5.7 %) - 1 (1.0 %)
Conventional therapy group: Antispastic medications, non-pharmacological therapies and aids
First quarter (n = 110) Second quarter (n = 98) Third quarter (n = 91) Fourth quarter (n = 84)
Oral medication 67 (60.9 %) 66 (67.3 %) 63 (69.2 %) 58 (69.0 %)
Physical therapy 68 (61.8 %) 59 (60.2 %) 54 (54.5 %) 52 (61.9 %)
Occupational therapy 15 (13.6 %) 11 (11.2 %) 11 (12.1 %) 8 (9.5 %)
Speech therapy 5 (4.6 %) 5 (5.1 %) 5 (5.5 %) 4 (4.8 %)
Other therapies 3 (2.7 %) 5 (5.1 %) - 1 (1.2 %)
Therapeutic aids 10 (11.0 %) 8 (8.2 %) 12 (13.2 %) 8 (9.5 %)
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of stroke and spasticity and Ashworth Scale score on base-
line exist. These findings indicate that there is no influ-
ence of external factors on therapeutic success.
Efficacy, tolerability and compliance
At study end the overall efficacy of antispastic therapy
was rated as ‘very good’ or ‘good’ by physicians for
90.0 % of patients in the INCO group, but only for
30.7 % in the CON group. Similarly 91.8 % of the physi-
cians rated the tolerability of the treatment with incobo-
tulinumtoxinA as ‚very good’, but only 13.3 % of the
CON group. For 62.7 % of the patients in this group the
physicians rated the tolerability as “good”. Adherence of
the patients to the antispastic therapy is rated as ‘very
good’ by physicians for 81.8 % patients of the INCO
group, whereas the respective value in the control group
is 21.3 %.
Functional disability
In all four domains of the 4-point scale DAS significant
improvements from baseline to study end were found in
the INCO group (mean changes for hygiene: −0.7 ± 1.1,
dressing −0.8 ± 1.1; limb position −1.0 ± 0.9, pain −0.8 ±
0.9; all p < 0.01, Wilcoxon-Mann–Whitney test). In the
CON group statistically significant changes could only be
demonstrated for “hygiene” (−0.2 ± 0.8) and “limb position”
(−0.3 ± 0.7) (both p < 0.01).
Quality of life
Patients in the CON group (mean baseline score 35.5 ± 9.3)
disposed marginally better health state values with respect
to ‘physical health’ at baseline than patients in the INCO
group (mean baseline score 33.6 ± 7.8). In the dimension
‘mental health’ baseline values were slightly higher in the
INCO group (mean baseline score 42.8 ± 14.8) than in the
CON group (mean baseline score 37.8 ± 14.4) (see Fig. 1).
After one year of antispastic therapy the INCO group
demonstrated clear and significant improvement in
mean physical health score by 8.0 ± 8.6 (p < 0.01), com-
pared to a change of 0.8 ± 7.9 (p = 0.43) in the CON
group. ‘Mental health’ score improved significantly in
both groups, however stronger in the INCO group:
10.8 ± 16.2 (p < 0.01) compared to 5.7 ± 13 (p = 0.02).
Table 4 Responder analyses at study end after 1-year of treatment






Shoulder adduction/internal rotation 56.4 73.9 62.9 15.5 <0.01 <0.01 <0.01
Shoulder abduction 65.5 100 73.0 19.7 <0.01 <0.01 <0.01
Shoulder elevation 66.7 88.9 72.7 20.6 <0.01 <0.01 <0.01
Flexed elbow 78.3 92.9 83.8 26.9 <0.01 <0.01 <0.01
Forearm pronation 81.4 73.7 79.0 22.0 <0.01 <0.01 <0.01
Flexed wrist 82.1 94.7 86.2 26.6 <0.01 <0.01 <0.01
Thumb-in-palm 77.8 81.3 78.8 20.0 <0.01 <0.01 <0.01
Clenched fist 79.1 95.2 84.4 22.2 <0.01 <0.01 <0.01
Intrinsic-plus-position of the hand 73.3 100 78.9 19.5 <0.01 <0.01 <0.01
Responder rates (%); response was definded as ≥ 1-point improvement on the Ashworth Scale for all treated muscle groups at study end; Fisher’s exact test was
used for group comparisons
Fig. 1 SF-12 – Dimensions ’Physical Health‘ and ‘Mental Health’.
a Physical Health Score from baseline to study end. b Mental Health
Score from baseline to study end. Mean values; p-values: change from
baseline to study end, one-sample t-test for dependent samples
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Changes in patients receiving incobotulinumtoxinA in-
creased significantly (p < 0.01) independent from their
BoNT/A pretreatment status (data not shown).
Adverse events and adverse drug reactions
A total of 81 Adverse Events (AE) were documented, of
which 43 were classified as Serious Adverse Events
(SAE) (21 INCO, 22 CON). Testing of the proportion of
AEs and SAEs by groups yielded no statistically significant
differences between groups (p = 0.439 resp. p = 0.452).
There was no causal relation of AEs to the study medica-
tion. Adverse Drug Reactions (ADR) occurred only in one
patient (male, 72 years) in the INCO group that reported
a mild loss of strength in the left arm.
Costs
The highest costs in the INCO group were caused by
drugs (3,386 €) followed by costs of nursing care (3,089 €).
Each of these cost centers account for about one third of
total therapy costs (see Table 5). According to the docu-
mented treatment rates costs for non-pharmacological
therapies in this group were higher than in the CON
group. The average amount of drug costs in the CON
group is very low and amounts to 193 €. About 50 % of
total direct costs in the CON group is composed by
costs in nursing care. Overall total costs, including re-
duction in earning capacity, are about twice as high in
the INCO group as compared to the CON group
(10,268 € vs. 4,794 €).
Cost-utility analysis
Despite costs being twice as high for patients treated
with incobotulinumtoxinA the INCO group shows more
favorable cost-utility ratios for every clinical pattern
evaluated in the responder analysis of change of muscle
tone (compare Table 6). The highest cost-utility ratio in
the INCO group (shoulder adduction/internal rotation,
16,325 €) remains below the lowest cost-utility ratio in
the CON group (flexed elbow, 17,821 €). This result is
based on the responder rates, which are on average three
times higher in the INCO group, than in the CON group
reaching only placebo level. The best cost-utility ratios
for patients treated with incobotulinumtoxinA can be
found for the spastic patterns clenched fist, intrinsic-plus
position of the hand and the thumb-in-palm position.
Only with regards to the SF-12 dimension ‘mental health’
the CON group showed a more favorable cost-utility ratio.
Lowest incremental costs at all were calculated for the
gain in “physical health” in SF-12 in INCO group.
Discussion
To our knowledge this study is the first evaluation of
cost-effectiveness of incobotulinumtoxinA in compari-
son to conventional antispastic treatment of upper limb
spasticity in Germany.
In summary incobotulinumtoxinA proved more effective
than conventional therapy in the treatment of upper limb
spasticity over a 1-year treatment period in routine clinical
practice. Compared to conventional therapy muscle
tone decreased significantly (responder rates between
62.9–86.2 %, p < 0.01), connected to significant im-
provements in functional disability (all DAS domains,
p < 0.01) and quality of life (both SF-12 dimensions
mental and physical health, p < 0.01) after 1-one year of
treatment. Conventional therapy with responder rates
between 15.5 % and 26.9 % from baseline to study end,
only partially resulted in functional improvements and im-
proved quality of life; changes in DAS domains “hygiene”
and “limb position” (p < 0.01) and mental health dimen-
sion of SF-12 (p = 0.02) were significant from baseline in
this group.
The non-interventional design was chosen to describe
the clinical routine practice in spasticity treatment in
different sites and with different treatment options in
Germany. Group comparisons of non-interventional
parallel-group studies might be biased to the non-
randomized patient selection, however the big advan-
tage of this trial design is the description of current
treatment situation, effectiveness of treatments and
consecutive health care costs.
Spasticity should be treated in a multidisciplinary team
approach including physical and occupational therapies
as well as antispastic medications. Physiotherapy is recom-
mended as basic treatment for all types of spasticity, botu-
linum toxin as the treatment of choice for focal, multifocal
and segmental spasticity. Particularly in stroke patients
coexisting muscle weakness may be aggravated by systemic
anticholinergic medications and is therefore only recom-
mended as adjuvant therapy, in particular for severe general
spasticity in immobile patients [7]. However, these guideline
recommendations have so far not been implemented in
routine health care practice in Germany [12]. An analysis





Ambulatory medical treatment 175 217
Drugs 3,386 193
Hospitalizations (including rehabilitation measures) 40 138
Non-pharmacological therapies 1,408 998
Medical devices/aids 79 12
Nursing home care 3,089 2,203
Total direct costs 8,188 3,806
Reduction in earning capacity 2,081 988
Total costs 10,268 4,794
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of German statutory health insurance data revealed a de-
crease of patients with post-stroke spasticity receiving
physiotherapy after transition into ambulatory care (48 %
vs. 89 % for inpatient care). Oral muscle relaxants were
used in 13 % of the patients in this database; none received
intrathecal baclofen or even botulinum toxin [12].
The results of the primary efficacy outcome, the re-
sponder analysis of muscle tone reduction, clearly dem-
onstrate the superiority of the treatment approach in the
INCO group with regular incobotulinumtoxinA injec-
tions. Responder rates were significantly higher in all
measured muscle groups than with conventional therapy
alone. The results are comparable to a placebo-controlled
trial [20] and its corresponding long-term open-label inco-
botulinumtoxinA study [21]. In both trials stable antispas-
tic medication and physical and occupational therapy
regimens were permitted. The results are also in line with
long-term investigations with other BoNT/A preparations
in the treatment of spasticity of various etiologies including
stroke [22–24].
Higher levels of care at study baseline and rates of
early retirement indicate that patients in the INCO
group were more severely affected than the CON group.
Though patients were slightly younger in the INCO
group their diagnosis of stroke and spasticity had oc-
curred earlier than in the CON group. Nevertheless a
logistic-regression analysis does not show a meaningful
influence of age, disease duration, different Ashworth
scores at baseline or any other factors including gender,
body size and weight, BMI and treatment group on
treatment response.
The burden of spasticity in surviving stroke patients is
substantial. Spasticity leads to functional disability in
daily living and reduces quality of life. In a German
prospective cohort study [3] with acute stroke patients,
those who developed spasticity 6 months later showed a
lower mean score in EQ-5D (n = 75, mean 53.6) com-
pared to patients without developing spasticity (n = 80,
mean, 62.7; p < 0.001). In another study with 66 stroke
survivors the impact of spasticity on QoL was determined
18 months after stroke [25]. Patients with spasticity (n = 13)
had significantly lower scores on the physical function do-
main of SF-36 (p < 0.01) compared to those without spasti-
city (n = 28). In a large retrospective analysis of 328 stroke
survivors those patients with spasticity had significant lower
SF-12 scores (physical component) and EQ-5D scores
(p < 0.05) compared to those not reporting spasticity
[2, 26]. Increased functional impairment measured with
DAS in patients with upper limb post-stroke spasticity
was also found to be associated with diminished QoL
measured with EQ-5D score [27].
At present only few data exist describing the costs spe-
cific to post-stroke spasticity treatment. In the first year
after stroke patients with spasticity cause four times
higher direct costs compared to patients without
spasticity [28]. The primary drivers in costs were hos-
pital care and help at home/residential care. Increased
costs were strongly associated with worsening functional
ability (rs = 0.624, p < 0.001) and with increasing muscle
tone (rs = 0.524, p < 0.001).
Total costs in the INCO group are about twice as high
as in the CON group. Particularly drug costs accounted
for about one third of total costs in the INCO group,
but for less than 5 % in the control group. Other major
contributors to higher costs in the INCO group were
nursing home care, accounting for another third of total
costs, and the reduction in earning capacity accounting
for about 20 %. At study baseline 60.6 % of patients in
Table 6 Overview of cost-utility ratios and ICER
Utility parameter INCO CON ICER
Responder rate in Ashworth Score per clinical pattern Responder rate Cost-utility ratio Responder rate Cost-utility ratio
Shoulder adduction/internal rotation 62.9 % 16,325 € 15.5 % 30,929 € 11,549 €
Shoulder abduction 73.0 % 14,066 € 19.7 % 24,335 € 10,271 €
Shoulder elevation 72.7 % 14,124 € 20.6 % 23,272 € 10,507 €
Flexed elbow 83.8 % 12,253 € 26.9 % 17,821 € 9,621 €
Pronated forearm 79.0 % 12,998 € 22.0 % 21,791 € 9,604 €
Flexed wrist 86.2 % 11,912 € 26.6 % 18,022 € 9,185 €
Thumb-in-palm 78.8 % 13,031 € 20.0 % 23,970 € 9,310 €
Clenched fist 84.4 % 12,166 € 22.2 % 21,595 € 8,801 €
Intrinsic-Plus-position (hand) 78.9 % 13,014 € 19.5 % 24,585 € 9,216 €
Improvement in SF-12 dimension Improvement Cost-utility ratio Improvement Cost-utility ratio ICER
Physical Health 7.96 1,290 € 0.83 5,776 € 768 €
Mental Health 10.75 955 € 5.71 840 € 1086 €
Incremental Cost-Effectiveness Ratio (ICER) = (Total costs INCO – Total costs CON)/(Utility value INCO – Utility value CON)
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the INCO group, but only 20.4 % in the CON group
were prematurely retired due to spasticity. Additionally
79.6 % of INCO patients compared to 64.4 % of CON
patients received payments from nursing care insurance
due to documented levels of care needed resulting in
higher nursing home care costs.
The total costs in relation to efficacy results of the two
treatment groups, the cost-utility ratios, demonstrate
consistently better results for the INCO group. Best re-
sults were achieved with regards to the “physical health”
dimension of quality of life score SF-12, since patients
with only conventional therapy failed to improve their
“physical health”. The cost-utility ratio for INCO was
4.5-times smaller than for the CON group. The only cost-
utility ratio with more favorable results for conventional
treatment compared to INCO (840 € vs. 955 €) was to the
one for the “mental health” dimension of the SF-12.
Only few studies have so far been conducted to evalu-
ate cost-effectiveness of antispasticity treatment and in
particular cost-effectiveness of botulium toxin treatment.
The BoTULS trial investigated cost-effectiveness of
abobotulinumtoxinA (Dysport®) plus a specified 4-week
upper limb therapy program (n = 170) compared to the
therapy program alone (n = 163) in a randomized con-
trolled setting in UK over a 1-year period [28, 29]. Arm
function was measured by the Action Research Arm
Test (ARAT) assessing “active” arm function. There was
no significant difference between the groups for the pri-
mary outcome of improved arm function after one
month of treatment (19.5 % control group vs. 25.1 %
intervention group, p = 0.232). Health related quality of
life was assessed using EuroQoL (EQ-5D). Differences
between the groups favoring BoNT/A treatment were
only found in EQ-5D domain “pain” 3 months after
study start, and “anxiety/depression” 12 months after
study start. Cost-effectiveness analysis only covered three
months from randomization. The overall mean costs per
participant were higher in the botulinum toxin group, al-
though the difference was not significant. Biggest con-
tributor to total costs for both groups was costs for
other health care and social services contacts. The base
case incremental cost-effectiveness ratio for botulinum
toxin A plus therapy was 93,500£ per QALY gained.
The international onabotulinumtoxinA (Botox®) eco-
nomic spasticity trial evaluated patient outcomes and
costs of onabotulinumtoxinA plus standard care ver-
sus standard care alone in a randomized double-blind
placebo-controlled trial design with an open-label ex-
tension period in focal upper and lower limb spasticity
after stroke [30, 31]. The primary endpoint was the
number of patients who achieved their investigator-
rated principal active functional goal measured by
Goal Attainment Scaling 10 weeks after their second
injection at week 24. Similarly to the BoTULS trial the
proportion of patients achieving their principal active
functional goal with onabotulinumtoxinA plus stand-
ard of care was not statistically different from placebo
plus standard of care. However, secondary passive
functional goal achievement differed significantly at
week 24: 60.6 % of patients in the treatment group
and 38.6 % in the control group (p = 0.016), achieved
the passive functional goal. Results of changes in EQ-
5D, treatment costs or cost-effectiveness analysis have
not been published so far.
In our study incobotulinumtoxinA treatment demon-
strated superior results in muscle tone reduction com-
pared to conventional therapy and significantly improved
functional impairment as well as quality of life. One of the
main cost drivers in the INCO group were drug costs.
However cost-utility analysis clearly favored incobotuli-
numtoxinA treatment in comparison to conventional
therapy alone and is recommended with level A in na-
tional and international guidelines.
Conclusions
Due to different trial designs, national varying health care
systems and different approaches for calculating cost-
effectiveness the comparison of health economic studies is
hardly possible. In our study, which collected data from
routine clinical practice incobotulinumtoxinA treatment
demonstrated superior results in muscle tone reduction
compared to conventional therapy and significantly im-
proved functional impairment as well as quality of life.
One of the main cost drivers in the INCO group were
drug costs. However cost-utility analysis clearly favored
incobotulinumtoxinA treatment in comparison to conven-
tional therapy alone. In our view the results underline the
level A recommendation of national and international
guidelines for treatment of post-stroke spasticity with
botulinum toxin. The reasons are unclear, but the treat-
ment rates in this study indicate, that spasticity treatment
according to guidelines seems not comprehensively imple-
mented in Germany.
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